Pharmala Biotech Holdings Inc (MDMA) Quote

PharmAla Reaches Agreement In Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License

https://pharmala.ca/media/2024/11/pharmala-reaches-agreement-in-principle-to-supply-mdma-to-clinical-trial-in-exchange-for-full-data-license

News: PharmAla to supply LaNeo MDMA for Clinical Trial at Yale

https://pharmala.ca/media/2024/11/pharmala-to-supply-laneo-mdma-for-clinical-trial-at-yale

PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA Press Release | 10/21/2024

https://www.otcmarkets.com/stock/MDXXF/news/PharmAla-to-supply-Mt-Sinai-Hospital-with-LaNeo-MDMA?id=456329

PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA Press Release | 10/08/2024

https://www.otcmarkets.com/stock/MDXXF/news/PharmAla-to-supply-the-University-of-Texas-San-Antonio-with-novel-dosage-form-of-LaNeo-MDMA?id=455196

PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMAPress Release | 10/02/2024
https://www.otcmarkets.com/stock/MDXXF/news/PharmAla-to-supply-Harvard-Medical-Schools-Maclean-Hospital-with-LaNeo-MDMA?id=454666

PharmAla to supply Johns Hopkins Medicine for Clinical TrialPress Release | 09/11/2024


https://www.otcmarkets.com/stock/MDXXF/news/PharmAla-to-supply-Johns-Hopkins-Medicine-for-Clinical-Trial?id=452770

$MDMA New Short Call: Shorts in at 30 cents today. Stay tuned tomorrow for details of its pending doom. Last call 34% in less than 2 days.

$MDMA SHORT ALERT!!!

Company up on lousy $50,000 deal.... Shorts in at 38 cents CDN.

Quick 30%

Act Now!!!

$MDMA is looking like the perfect short. The SP is racing up and the company only has 700K left with shares doubling up in the past 12 months. Over the past 12 months cash went down by 1.2 million.

It looks like this IPO has gone similarly to all psych companies have. The industry needs a massive correction, but that cannot happen until government stop obsessing over vaccines and start promoting alternative solutions to the gigantic mental health crisis ongoing and perpetuating daily while being ignored. MDMA looks promising and I'll be keeping a very close eye on its news and resulting share price.